Serum uric acid is associated with damage in patients with systemic lupus erythematosus

Claudia Elera-Fitzcarrald 1,2, Cristina Reátegui-Sokolova,2,3 Rocio Violeta Gamboa-Carmona,2,4 Mariela Medina,2 Francisco Zevallos,2 Victor Román Pimentel-Quiroz 1,2, Jorge Mariano Cucho-Venegas,2 José Alvaro Lozano,2 Zoila Rodriguez-Bellido,2,4 Cesar Augusto Pastor-Asurza,2,4 Risto Alfredo Perich-Campos,2,4 Graciela S Alarcón,5,6 Manuel Francisco Ugarte-Gil 1,2

ABSTRACT

Introduction Serum uric acid levels have been reported as predictors of cardiovascular, pulmonary, neurological and renal morbidity in patients with SLE. However, their role in cumulative global damage in these patients has not yet been determined.

Objective To determine whether serum uric acid levels are associated with new damage in patients with SLE.

Methods This is a longitudinal study of patients with SLE from the Almenara Lupus Cohort, which began in 2012. At each visit, demographic and clinical characteristics were evaluated, such as activity (Systemic Lupus Erythematosus Disease Activity Index-2K or SLEDAI-2K) and cumulative damage (Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index or SDI). Treatment (glucocorticoids, immunosuppressive drugs and antimalarials) was also recorded. Univariable and multivariable Cox regression models were used to determine the impact of serum uric acid levels on the risk of new damage.

Results We evaluated 237 patients, with a mean age (SD) at diagnosis of 35.9 (13.1) years; 220 patients (92.8%) were women, and the duration of the disease was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Serum uric acid level was 4.5 (1.4) mg/dL. Follow-up time was 3.1 (1.3) years, and 112 (47.3%) patients accrued damage during follow-up. In univariable and multivariable analyses, serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively).

Conclusion Higher serum uric acid levels are associated with global damage in patients with SLE.

INTRODUCTION

In humans, uric acid is the final product of purine metabolism. At physiological pH, uric acid is found predominantly (98%–99%) as a deprotonated anion. The solubility of uric acid at normal physiological pH is generally given at 6.8 mg/dL, with reference ranges for uric acid of 3.5–7.2 mg/dL (210–430 μmol/L) and 2.6–6.0 mg/dL (155–360 μmol/L) in younger men and premenopausal women, respectively.1 Hyperuricaemia is the result of increased production or decreased excretion of uric acid.2 Uric acid levels have been associated with increased risk of heart mortality,3 increased risk of kidney disease4 and as a predictor of metabolic syndrome.5 In patients with SLE, uric acid has been recognised as a potential marker of endothelial dysfunction and renal disease, as an association has been found between active lupus nephritis and hyperuricaemia,6 as well as with cerebral infarction and peripheral neuropathy.7 Likewise, uric acid levels are useful in predicting the future development of pulmonary hypertension in patients with SLE with normal basal systolic pulmonary artery pressure.8 In addition, serum uric acid levels have been reported as predictor of increased risk of kidney damage.9 Thus, the objective of this study was to determine whether serum uric acid levels are associated with the occurrence of new damage in patients with SLE.

METHODS

Patients

Starting in January 2012, all patients with SLE presenting to the Rheumatology Department of the Hospital Guillermo Almenara Irigoyen in Lima, Peru, have been invited to participate in the Almenara Lupus Cohort. All patients met the 1997 American College of Rheumatology (ACR) criteria when entering the cohort. Patients with at least two visits were included. Demographic data included gender, age at diagnosis,
Comorbidity Index. Therapeutic variables included the disease duration and comorbidities using the Charlson Collaborating Clinics/ACR Damage Index (SDI),11 damage (assessed using the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI)),11 disease duration and comorbidities using the Charlson Comorbidity Index.12 Therapeutic variables included the use of glucocorticoids (current dose and time of exposure). Similarly, the use of immunosuppressive and antimalarial drugs was recorded as current, past or never administered. A past user was defined as those patients receiving treatment until the day before the assessment. All variables were assessed at baseline, with the exception of new damage, which was assessed at subsequent visits.

Statistical analyses
Univariable and multivariable Cox regression models were performed to determine the impact of serum uric acid level on the risk of new damage. Multivariable models were adjusted for age at diagnosis, disease duration, socioeconomic status, educational level, SLEDAI-2K, SDI, comorbidities, and use of prednisone, immunosuppressive and antimalarial drugs. P<0.05 was considered significant in all analyses. All statistical analyses were performed using SPSS V.26.0.

RESULTS
Two hundred and thirty-seven patients with SLE were evaluated. The mean age (SD) at diagnosis was 35.9 (13.1) years, 220 patients (92.8%) were women, almost all were Mestizo (European and Native American ancestry), and the disease duration at baseline was 7.3 (6.6) years. The mean SLEDAI-2K and SDI scores were 5.1 (4.2) and 0.9 (1.3), respectively. Charlson Comorbidity Index score was 0.5 (0.9). Serum uric acid levels were 4.5 (1.4) mg/dL; 24 (10.1%) patients had uric acid levels above the normal limit. The current mean dose of prednisone was 7.1 (6.4) mg/day. Time of exposure to prednisone was 6.9 (6.2) years, and follow-up time was 3.1 (1.3) years. One hundred and twelve (47.3%) patients accumulated some type of damage during follow-up. Patient characteristics are shown in table 1.

Organ damage per domain is described in table 2. In univariable and multivariable analyses (adjusting for variables known to have an impact on damage accrual), serum uric acid levels were associated with new damage (HR=1.141 (95% CI 1.016 to 1.282), p=0.026; HR=1.189 (95% CI 1.025 to 1.378), p=0.022, respectively), as shown in table 3.

DISCUSSION
The association between uric acid levels and damage accrual in patients with SLE was evaluated, and serum uric acid level was found to be associated with the development of new damage in these patients. Previous studies have found an association between hyperuricaemia and hypertension,13 metabolic syndrome14 and renal disease,2 as well as with organ failure or damage,15 especially renal.16

In several autoimmune diseases, high serum uric acid levels play an important role in the development and risk of certain comorbidities; for example, in rheumatoid arthritis, uric acid is a cardiovascular risk factor reflected in the increased thickness of the carotid artery.17 On the other hand, in systemic sclerosis, Gigante et al18 found that serum uric acid levels were higher in those with more microvascular damage as compared with those with less microvascular damage.

Taraborelli et al19 examined the effect of disease duration of 511 patients with SLE on damage; this study showed that, at 1 year of follow-up, about 40% of patients had some damage: usually mild or moderate. The prevalence of damage progressively increased over time, starting from a mean SDI score of 0.6 (SD: 0.89) at year 1 to 0.9 (SD: 1.19) at 5 years and 3.7 (SD: 1.5) at 35 years of follow-up. Bruce et al20 found that increasing age had a significant influence on the probability of

| Table 1 Characteristics of patients with SLE |
| Mean or n | SD or percentage |
| --- | --- |
| Age at diagnosis (years) | 35.9 | 13.1 |
| Gender, male | 17 | 7.2 |
| Socioeconomic status | | |
| High | 46 | 19.4 |
| Medium | 96 | 40.5 |
| Low | 95 | 40.1 |
| Educational level (years) | 13.1 | 3.2 |
| Disease duration (years) | 7.4 | 6.7 |
| Uric acid level (mg/dL) | 4.6 | 1.5 |
| SLEDAI-2K | 5.2 | 4.3 |
| SDI | 1.0 | 1.3 |
| Charlson Comorbidity Index | 0.5 | 0.9 |
| Prednisone current dose (mg/day) | 7.2 | 6.4 |
| Time of exposure to prednisone (years) | 6.9 | 6.2 |
| Antimalarial use | | |
| Never | 20 | 8.4 |
| Past | 28 | 11.8 |
| Current | 189 | 79.7 |
| Immunosuppressive drug use | | |
| Never | 60 | 25.3 |
| Past | 60 | 25.3 |
| Current | 117 | 49.4 |
| Follow-up time | 3.1 | 1.3 |

SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2K.
## Table 2  Damage per domain

|                          | Not new damage | New damage | P value |
|--------------------------|----------------|------------|---------|
|                          | n (%)          | Uric acid, mean (SD) | n (%)          | Uric acid, mean (SD) |   |
| Global score             | 125            | 4.37 (1.36) | 112            | 4.83 (1.46) | 0.014 |
| Domains                  |                |            |                |               |     |
| Ocular                   | 223            | 4.58 (1.48) | 14             | 4.61 (1.27) | 0.942 |
| Neuropsychiatric         | 197            | 4.63 (1.52) | 40             | 4.38 (1.11) | 0.323 |
| Renal                    | 198            | 4.31 (1.21) | 22             | 5.88 (1.57) | <0.001 |
| Lung                     | 215            | 4.58 (1.44) | 22             | 4.66 (1.71) | 0.796 |
| Cardiac                  | 233            | 4.61 (1.46) | 4              | 3.43 (0.87) | 0.109 |
| Peripheral vascular      | 235            | 4.59 (1.47) | 2              | 3.75 (0.48) | 0.418 |
| Gastrointestinal         | 231            | 4.61 (1.47) | 6              | 3.53 (0.73) | 0.074 |
| Musculoskeletal          | 200            | 4.51 (1.44) | 37             | 4.98 (1.57) | 0.078 |
| Cutaneous                | 236            | 4.59 (1.47) | 1              | 4.80 | 0.884 |
| Gonadal                  | 115            | 4.15 (1.10) | 6              | 5.20 (0.78) | 0.023 |
| Diabetes                 | 223            | 4.56 (1.45) | 3              | 4.40 (0.36) | 0.852 |
| Cancer                   | 233            | 4.57 (1.46) | 4              | 5.43 (1.50) | 0.248 |

Table 3  Factors associated with the occurrence of new damage (univariable and multivariable analyses)

| Variables                       | HR (95% CI)       | P value | HR (95% CI)       | P value |
|---------------------------------|-------------------|---------|-------------------|---------|
| Uric acid level (mg/dL)         | 1.141 (1.016 to 1.282) | 0.026 | 1.197 (1.020 to 1.403) | 0.028 |
| Age at diagnosis (years)        | 1.023 (1.009 to 1.038) | 0.001 | 1.038 (1.018 to 1.058) | <0.001 |
| Gender (male)                   | 1.005 (0.489 to 2.065) | 0.989 | 1.027 (0.455 to 2.321) | 0.949 |
| Socioeconomic status            |                   |         |                   |         |
| High                            | Ref               |         | Ref               |         |
| Medium                          | 1.239 (0.745 to 2.061) | 0.409 | 0.461 (0.174 to 1.223) | 0.120 |
| Low                             | 1.422 (0.950 to 2.129) | 0.087 | 1.023 (0.579 to 1.805) | 0.938 |
| Educational level (years)       | 0.940 (0.889 to 0.993) | 0.027 | 0.885 (0.793 to 0.988) | 0.029 |
| Disease duration (years)        | 1.032 (1.008 to 1.055) | 0.007 | 1.056 (1.006 to 1.109) | 0.029 |
| SLEDAI-2K                       | 1.040 (1.000 to 1.082) | 0.051 | 1.018 (0.971 to 1.068) | 0.457 |
| SDI                             | 1.283 (1.147 to 1.435) | <0.001 | 1.095 (0.836 to 1.320) | 0.960 |
| Creatinine level (mg/dL)        | 0.993 (0.882 to 1.118) | 0.907 | 0.979 (0.817 to 1.175) | 0.823 |
| Charlson Comorbidity Index      | 1.030 (0.854 to 1.243) | 0.755 | 0.853 (0.646 to 1.128) | 0.265 |
| Prednisone current dose (mg/day) | 0.993 (0.964 to 1.023) | 0.637 | 1.000 (0.965 to 1.037) | 0.994 |
| Time of exposure to prednisone (years) | 1.032 (1.006 to 1.058) | 0.016 | 1.001 (0.952 to 1.053) | 0.957 |
| Antimalarial use                 |                    |         |                   |         |
| Never                           | Ref               |         | Ref               |         |
| Past                            | 0.970 (0.466 to 2.017) | 0.934 | 1.372 (0.584 to 3.226) | 0.468 |
| Current                         | 0.708 (0.409 to 1.225) | 0.217 | 1.106 (0.587 to 2.082) | 0.756 |
| Immunosuppressive drug use      |                    |         |                   |         |
| Never                           | Ref               |         | Ref               |         |
| Past                            | 1.021 (0.597 to 1.744) | 0.940 | 1.191 (0.654 to 2.170) | 0.568 |
| Current                         | 1.420 (0.916 to 2.202) | 0.117 | 1.649 (0.997 to 2.728) | 0.051 |

Ref, reference; SDI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index-2K.
and found that higher daily prednisolone dose predicted disease damage.

In SLE, serum uric acid levels have been reported to be associated with several impairments, including renal, cardiovascular, pulmonary and neurological, which when analysed together may explain the impact on damage. Yang et al. found that serum uric acid level was associated with the development of lupus nephritis and previously we have reported that serum uric acid level predicts increased kidney damage. In the same way, Ugolini-Lopes et al. found that serum uric acid levels <6.05 mg/dL at 12 months of follow-up were a predictor of good long-term renal outcome in lupus nephritis. Likewise, in the study by Sabio et al., patients with hyperuricaemia presented a worse cardiovascular risk profile that included hypertension, obesity, high cholesterol levels, renal damage and metabolic syndrome; in addition, serum uric acid levels correlated with high levels of erythrocyte sedimentation rate, C reactive protein, fibrinogen and homocysteine. Similarly, Castillo-Martínez et al. demonstrated that serum uric acid levels greater than 7 mg/dL would increase the risk of developing pulmonary hypertension by 8.5 times. Similar findings have been reported by Kim et al., where a value greater than 6.5 mg/dL of uric acid would be reasonably accurate in predicting the presence of pulmonary hypertension. In addition, hyperuricaemia has been shown to be related to factors that would increase the risk of stroke, such as high blood pressure, hyperlipidaemia and history of arterial thrombosis, and has been independently associated with the occurrence of cerebrovascular events and polyneuropathy.

Uric acid can generate urate radicals when it is exposed to oxidising agents and it has itself been shown in an in vitro study to stimulate the synthesis of monocyte chemoattractant protein-1, interleukin-1b, interleukin-6 and tumour necrosis factor-a, all of which are proinflammatory molecules. In contrast, it also represents one of the most important low-molecular-mass antioxidants in the human biological fluids. It is a powerful scavenger of peroxyl radicals, hydroxyl radicals and singlet oxygen, and may contribute to increased lifespan in humans by providing protection against oxidative stress-provoked ageing and cancer. Also, uric acid is an oxidisable substrate for hemoprotein/H2O2 systems and is able to protect against oxidative damage by acting as an electron donor. Despite this, we did not demonstrate how low the uric acid level needs to be to avoid damage in patients with SLE.

Keeping uric acid levels low is recommended to avoid damage in SLE, as it has been observed in studies that increasing uric acid is related to anaemia in SLE, and also associated with the occurrence of stroke, peripheral neuropathy, hypertension, hyperlipidaemia and history of arterial thrombosis. Even normal values of uric acid have been associated with renal damage in patients with SLE.

This study has some limitations. As it is not an inception cohort, it is not possible to define if the interaction between serum uric acid levels and damage is bidirectional, that is, damage increases the level of serum uric acid and this in turn determines new damage. Other limitations include the fact that randomisation was not possible in terms of the type of treatment that patients received. In addition, some medications have not been recorded in the database, such as losartan. Finally, the cumulative dose of steroids could not be obtained since this is not an inception cohort. On the other hand, being a cohort of mostly Mestizo patients, the results cannot be extrapolated to patients from other ethnic groups. An important strength of this study, however, is that for the first time it is reported that higher serum uric acid levels are associated with global damage. It will be necessary to conduct longitudinal studies with a larger number of patients to confirm these findings.

In conclusion, we describe for the first time the association between uric acid levels and global damage in patients with SLE, independently of age at diagnosis, sex, disease duration, socioeconomic status, disease activity, comorbidities, prednisone use, antimalarials and immunosuppressive drugs at baseline.

Author affiliations
1 School of Medicine, Universidad Científica del Sur, Lima, Peru
2 Rheumatology, Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Lima, Peru
3 Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru
4 Universidad Nacional Mayor de San Marcos, Lima, Peru
5 Department of Medicine, Division of Clinical Immunology and Rheumatology, School of Medicine, The University of Alabama, Birmingham, Alabama, USA
6 Department of Medicine, Universidad Peruana Cayetana Heredia, Lima, Peru

Twitter Victor Román Pimentel-Quiroz @VictorioPQ and Manuel Francisco Ugarte-Gil @mugartegi

Contributors All authors were involved in drafting or revising this article critically for important intellectual content, and all approved the final version to be published. CE-F has full access to all of the data from the study and takes responsibility for their integrity and the accuracy of the analyses performed.

Funding This work was partially supported by an institutional grant from EsSalud (1483-GGCP-ESSALUD-2013, 1733-GGCP-ESSALUD-2014 and 04-JESt-ESSALUD-2016 2015, Kaelin Prize) and one from the Panamanian League of Associations for Rheumatology (PANLAR) (2015 PANLAR Prize).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study had been approved by the Institutional Review Board of Hospital Nacional Guillermo Almenara Irigoyen, EsSalud (3474-OCID-G-RAA-ESSALUD-11, 271-CEI-CID-G-RAA-ESSALUD-13, 302-CEI-ICD-G-RAA-14, 3027-OCID-G-RAA-ESSALUD-15). Patients who signed the informed consent were recruited into the cohort.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. If more information is needed, please contact MFU-G.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Claudia Elena Fitzcarrald http://orcid.org/0000-0001-7271-2523
Victor Roman Pimentel-Quiroz http://orcid.org/0000-0002-3638-7054
Manuel Francisco Ugarte-Gil http://orcid.org/0000-0003-1728-1999
REFERENCES

1 Desideri G, Castaldo G, Lombardi A, et al. Is it time to revise the normal range of serum uric acid levels? *Eur Rev Med Pharmacol Sci* 2014;18:1296–306.

2 Trevisi-Becerra A. Uric acid: the unknown uremic toxin. *Contrib Nephrol* 2018;192:25–33.

3 Stack AG, Hanley A, Casserly LF, et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. *QJM* 2013;106:647–58.

4 Storhaug HM, Toft I, Norvik JV, et al. Uric acid is associated with microalbuminuria and decreased glomerular filtration rate in the general population during 7 and 13 years of follow-up: the Tromso study. *BMC Nephrol* 2015;16:210.

5 Sui X, Church TS, Merivether RA, et al. Uric acid and the development of metabolic syndrome in women and men. *Metabolism* 2008;57:845–52.

6 Calich AL, Borba EF, Ugolini-Lopes MR, et al. Serum uric acid levels are associated with lupus nephritis in patients with normal renal function. *Clin Rheumatol* 2018;37:1223–8.

7 Sheihk M, Movassaghi S, Khaledi M, et al. Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease? *Rev Bras Reumatol* 2016;56:471–7.

8 Castillo-Martínez D, Marroquín-Fabián E, Lozada-Navarro AC, et al. Levels of uric acid may predict the future development of pulmonary hypertension in systemic lupus erythematosus: a seven-year follow-up study. *Lupus* 2016;25:61–6.

9 Reátegui-Sokolova C, Ugarte-Gil MF, Gamboa-Cárdenas RV, et al. Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. *Clin Rheumatol* 2017;36:845–52.

10 Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. *J Rheumatol* 2002;29:288–91.

11 Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international classifying cohorts (SLICC) inception cohort. *Ann Rheum Dis* 2007;66:1168–72.

12 Shaharir SS, Ghafor AHA, Said MSM, et al. A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis. *Lupus* 2014;23:436–42.

13 Yang Z, Liang Y, Xi W, et al. Association of serum uric acid with lupus nephritis in systemic lupus erythematosus. *Rheumatol Int* 2011;31:743–8.

14 Ugolini-Lopes MR, Gavinier SS, Leon E, et al. Is serum uric acid a predictor of long-term renal outcome in lupus nephritis? *Clin Rheumatol* 2019;38:2777–83.

15 Sabio JA, Vargas-Hitos JA, Mario J. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus: comments on the article by MOK et al. *Scand J Clin Lab Invest* 2019;39:527.

16 Kim K-J, Baek I-W, Park Y-J, et al. High levels of uric acid in systemic lupus erythematosus is associated with pulmonary hypertension. *Int J Rheumatol* 2015;18:524–32.

17 Shamsi FA, Hadi SM. Photoinduction of strand scission in DNA by uric acid and Cullin. *Free Radic Biol Med* 1999;19:189–96.

18 Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension* 2003;41:1287–93.

19 Ames BN, Cattach R, Schwiers E, et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc Natl Acad Sci U S A* 1981;78:6858–62.

20 Becker BF. Towards the physiological function of uric acid. *Free Radic Biol Med* 1993;14:615–31.

21 Re R, Pellegrini N, Power DJ, et al. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Radic Biol Med* 1999;26:1231–7.

22 Glantznis G, Tsimoyiannis E, Kappas A, et al. Uric acid and oxidative stress. *Curr Pharm Des* 2005;11:4145–51.

23 Yang Z, Liang Y, Li C, et al. Associations of serum urea, creatinine and uric acid with clinical and laboratory features in patients with systemic lupus erythematosus. *Rheumatol Int* 2012;32:2715–23.